Spero Therapeutics Inc (SPRO) — Cash Flow-to-Debt Ratio
Spero Therapeutics Inc (SPRO) has a Cash Flow-to-Debt Ratio of -0.84x as of December 2025, meaning its operating cash flow of $-8.35 Million could theoretically repay -1% of its total liabilities ($9.90 Million) in one year. Check SPRO cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Spero Therapeutics Inc Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Spero Therapeutics Inc across 11 annual periods. Also explore SPRO total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Spero Therapeutics Inc (2015–2025)
Year-by-year debt coverage analysis for Spero Therapeutics Inc. For market capitalisation and broader financial context, see Spero Therapeutics Inc market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.28x | $-12.62 Million | $9.90 Million | ▼ -250.5% |
| 2024 | -0.36x | $-23.44 Million | $64.42 Million | ▲ +16.7% |
| 2023 | -0.44x | $-32.99 Million | $75.50 Million | ▼ -176.3% |
| 2022 | -0.16x | $-7.73 Million | $48.87 Million | ▲ +79.6% |
| 2021 | -0.78x | $-64.35 Million | $82.78 Million | ▲ +80.6% |
| 2020 | -4.01x | $-85.87 Million | $21.41 Million | ▼ -152.8% |
| 2019 | -1.59x | $-50.02 Million | $31.53 Million | ▲ +47.3% |
| 2018 | -3.01x | $-39.62 Million | $13.15 Million | ▲ +34.3% |
| 2017 | -4.59x | $-39.11 Million | $8.52 Million | ▼ -17.4% |
| 2016 | -3.91x | $-28.96 Million | $7.41 Million | ▼ -202.3% |
| 2015 | -1.29x | $-9.61 Million | $7.43 Million | — |